Esperion Therapeutics (NASDAQ:ESPR) Earns “Buy” Rating from Cowen

Cowen reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research report sent to investors on Thursday morning, AnalystRatings.com reports. Cowen currently has a $80.00 target price on the biopharmaceutical company’s stock.

A number of other analysts have also weighed in on the stock. Credit Suisse Group set a €50.00 ($58.14) target price on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a research report on Monday, May 6th. BidaskClub upgraded shares of Westport Fuel Systems from a hold rating to a buy rating in a report on Friday, July 12th. Citigroup set a $73.00 price target on shares of Esperion Therapeutics and gave the stock a buy rating in a report on Tuesday, May 28th. Stifel Nicolaus reiterated a buy rating on shares of Esperion Therapeutics in a report on Thursday, June 13th. Finally, Goldman Sachs Group upgraded shares of Koninklijke KPN from a neutral rating to a buy rating in a report on Wednesday, May 29th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of Buy and a consensus target price of $74.00.

Shares of Esperion Therapeutics stock opened at $43.10 on Thursday. Esperion Therapeutics has a fifty-two week low of $36.06 and a fifty-two week high of $60.99. The company has a 50 day moving average of $48.00.



Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $3.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $2.43. The company had revenue of $145.42 million during the quarter, compared to analyst estimates of $69.35 million. During the same quarter in the prior year, the business earned ($1.73) EPS. Equities research analysts expect that Esperion Therapeutics will post -2.65 EPS for the current fiscal year.

In other news, CEO Timothy M. Mayleben bought 5,000 shares of the stock in a transaction that occurred on Friday, June 28th. The stock was acquired at an average price of $46.00 per share, with a total value of $230,000.00. Following the completion of the purchase, the chief executive officer now directly owns 66,163 shares of the company’s stock, valued at $3,043,498. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 7.70% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in ESPR. FMR LLC raised its stake in Esperion Therapeutics by 43.8% during the fourth quarter. FMR LLC now owns 739,289 shares of the biopharmaceutical company’s stock worth $34,007,000 after buying an additional 225,205 shares during the last quarter. Spark Investment Management LLC raised its stake in Esperion Therapeutics by 72.1% during the first quarter. Spark Investment Management LLC now owns 390,900 shares of the biopharmaceutical company’s stock worth $15,694,000 after buying an additional 163,800 shares during the last quarter. Rhenman & Partners Asset Management AB raised its stake in Esperion Therapeutics by 35.5% during the first quarter. Rhenman & Partners Asset Management AB now owns 479,767 shares of the biopharmaceutical company’s stock worth $19,263,000 after buying an additional 125,806 shares during the last quarter. Norges Bank bought a new position in Esperion Therapeutics during the fourth quarter worth $5,536,000. Finally, Wasatch Advisors Inc. raised its stake in Esperion Therapeutics by 13.4% during the first quarter. Wasatch Advisors Inc. now owns 637,789 shares of the biopharmaceutical company’s stock worth $25,607,000 after buying an additional 75,165 shares during the last quarter.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Recommended Story: Leveraged Buyout (LBO) Explained

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.